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Abstract
Introduction Vogt–Koyanagi–Harada (VKH) prognosis
depends on early recognition and treatment; chronic disease
may be developed when either delayed or inadequate
treatment is performed, whereas other cases despite correct
treatment are refractory to different drugs and also become
chronic. We report a case of refractory VKH controlled with
rituximab treatment.
Case report A 41-year-old female with painful visual loss
and headache was examined. (VA 0.4 in RE and hand
movements (HM) in LE). Retinal examination demonstrated
multiple serous retinal detachments in both eyes. High-dose
oral steroids were started, followed by progressive tapering of
prednisone. New acute anterior and posterior relapses were
achieved, and other immunommodulators were progressively
added—new high-dose steroid treatment, adalimumab,
cyclosporine, and methotrexate—but patient had new
anterior and posterior recurrences associated with tinnitus
and headache. Thus, an infusion of 1 g of rituximab was
administered after 15 months follow-up; the VA was 0.2
in RE and counting fingers in LE. Three additional doses
of 1 g each were administered 1, 6, and 16 months later.
We have achieved a final VA after 34 months follow-up
of 0.2 in RE and HM in LE, with definitive control of
inflammation, without acute relapses since rituximab was
administered.
Conclusion After searching PubMed/Medline, this is the
first report of VKH disease treated with rituximab.
Additional studies are warranted to confirm the efficacy of
this new approach for inflammatory control in refractory
cases of VKH disease.
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Introduction
Vogt–Koyanagi–Harada (VKH) disease is a T-cell mediated
autoimmune disorder with an acute phase of severe bilateral
panuveitis and exudative retinal detachment. Patients
adequately treated with high-dose systemic corticosteroids
at the onset of the disease frequently have rapid resolution
of inflammation with good visual outcome [1]. However,
more than half of these patients, particularly those who
receive either delayed or inadequate treatment, may develop
chronic disease with consequent poor visual prognosis due
to cataract, glaucoma, subretinal fibrosis, choroidal neo-
vascularization, or choroidal atrophy [2]. These complica-
tions are accompanied by alterations in the retinal pigment
epithelium in the form of hypo or hyperplasia or granular
changes leading to a sunset glow appearance associated in
some cases with Dalen-Fuchs nodules [3]. Thus, to prevent
recurrences or to control these when chronic disease is
developed, in non-responsive patients or when corticosteroid
side effects are not well tolerated, other immunomodulatory
agents may be needed (corticosteroid-saving agents) [4].
Rituximab is a human–murine chimeric monoclonal
antibody targeting CD20, a transmembrane protein present
on immature and mature B cells. It was first approved for
the treatment of non-Hodgkin's B-cell lymphoma, and it is
very effective for depleting both normal and malignant
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CD20 B cells in vivo. There are only a few publications
about the efficacy and tolerability of rituximab treatment in
patients with autoimmune ocular inflammatory diseases. It
has been used in cases of refractory endogenous anterior
uveitis and Wegener's granulomatosis associated with
peripheral ulcerative keratitis [5, 6]. Other uses in oph-
thalmology have been reported, such as corticosteroid-
resistant thyroid-associated ophthalmopathy or in patients
with juvenile idiopathic arthritis-associated uveitis [7, 8].
In an automatic search in PubMed/Medline, we did not
find any report about the use of rituximab for either acute or
chronic VKH.
Case report
A 41-year-old Caucasian female from Argentina attended to
our department complaining of bilateral painful visual loss,
associated with headache and tinnitus.
Her best corrected visual acuity (BCVA) was 0.4 in her
right eye (RE) and counting fingers in her left eye (LE).
The anterior chamber showed perikeratic hyperemia,
moderate anterior chamber flare, and 1+ Tyndall phenom-
enon in both eyes. Fundus examination evidenced bilateral
disc edema and multifocal serous retinal detachment with
foveal involvement. Fluorescein angiography revealed late
pinpoint hyperfluorescence. Optical coherence tomography
showed multilobulated retinal serous detachment. Lumbar
puncture revealed pleocytosis with polymorphonuclear cells
(Fig. 1).
High-dose oral steroid treatment was started (1 g daily of
methylprednisolone for 3 days), followed by gradual
tapering of oral prednisone, achieving a significant im-
provement of BCVA (0.6 and 0.4). Three months later, a
new episode of posterior uveitis was evidenced, decreasing
VA to 0.05 in her RE and 0.02 in her LE. Due to this
exacerbation, treatment with new high-dose oral corticoste-
roid dose, bilateral intravitreal injection of ranibizumab and
dexamethasone and adalimumab (Humira®) every 15 days
was performed. However, a new relapse of anterior and
posterior inflammation occurred, so cyclosporine (200 mg
daily) and methotrexate (17.5 mg weekly) were added to
the treatment (Fig. 2). Despite this combination therapy,
further constant recurrences of anterior chamber inflamma-
Fig. 1 a, b. Color fundus
images of right and left eye
showed disc edema and multi-
focal serous retinal detachment
with foveal involvement.
c, d. Fluorescein angiography
photographs of both eyes
revealed characteristic pinpoint
hyperfluorescence in intermedi-
ate time. e, f. Time domain
optical coherence tomography
cross-sectional horizontal image
showed typical multilobulated
retinal serous detachment in
both eyes
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tion, retinal fluid relapses, tinnitus, and headache were
registered; thus, infusion of 1 g of rituximab was performed
(15 months after onset of symptoms). BCVA at this moment
was 0.2 in her RE and hands motion (HM) in her LE. Three
additional infusions of 1 g each were administered, 1, 6,
and 16 months later.
We obtained an optimal response with definitive control
of inflammation, without further relapses, since rituximab
was administered with no more decrease of BCVA at
34 months follow-up (Fig. 3).
Discussion
VKH prognosis depends on early recognition and aggressive
suppression of inflammation. The use of high-dose steroids
Fig. 2 Optical coherence tomog-
raphy cross-sectional horizontal
images of right and left eye
(RE and LE, respectively); a
(2 days follow-up) showed
response to high-dose corticoste-
roids in both eyes with decrease
of neuroretinal detachment that
is more evident after 2 weeks of
follow-up in b. c (3 months
follow-up) revealed first recur-
rence of macular detachment in
left eye first and later in right eye
(d, 4 months follow-up) treated
with a new high-dose oral corti-
costeroid therapy associated with
bilateral intravitreal injection of
ranibizumab and dexamethasone
and adalimumab every 15 days.
f (5 months follow-up) showed
reappearance of retinal detach-
ment, so we added treatment
with cyclosporine (100 mg per
day) and methotrexate (17.5 mg
weekly). g (7 months follow-up)
revealed macular detachment,
and examination showed
recurrence of anterior and
posterior inflammation with
tinnitus and headache; thus, we
started a first infusion of 1 g
of rituximab (15 months after
onset of symptoms)
Fig. 3 a, b. Color fundus pho-
tography of right and left eye,
respectively, after 30 months
follow-up showed typical
diffuse athrophy of retinal
pigment epithelium leading
to a characteristic image of
sunset-glow fundus. a (arrows)
revealed the presence of
Dalen-Fuchs nodules
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and other immunosuppressant agents has improved signifi-
cantly the visual outcome [9]; however, VKH may be a
disease difficult to treat with chronic relapses and may
require the use of other immunosuppressive drugs like TNF
blockers (infliximab or adalimumab) [10, 11] or different
combination therapy [4]. Intravitreal treatments with steroids
and vascular endothelial growth factor inhibitors have been
also reported as adjuvant possibilities with variable results
[12–14].
It may surprise the effectiveness of treatment with an anti
CD-20 monoclonal antibody in a T-cell-mediated disease;
however, changes in B and T lymphocytes after rituximab
treatment in multiple sclerosis have been analyzed. Unex-
pectedly, after B-cell depletion, a decline in cerebrospinal
fluid and blood T cells also occurred [15].
In this case, we started treatment with high-dose steroids,
but it was insufficient to control the disease. Patient had an
inadequate response to conventional immunosuppressive
treatment, such as methotrexate, cyclosporine, and TNF
blockers with constant recurrences. Consequently, we
initiated rituximab therapy with an optimal control of
inflammation. We achieved preservation of BCVA in RE,
without relapsing inflammatory episodes, since we have
started rituximab treatment.
Conclusion
To our knowledge, this is the first report of VKH disease
treated with rituximab. Although experience in treatment of
inflammatory eye disease with rituximab is reduced, this
therapy might be considered a therapeutic alternative for
treatment of patients with autoimmune ocular diseases,
particularly those who have not previously responded to
TNF blockers. Additional studies are warranted to confirm
the efficacy of this new approach for inflammatory control
in refractory cases of VKH disease.
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